Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

Abstract

Taxanes, mainly paclitaxel and docetaxel, the microtubule stabilizers, have been well known for being the first-line therapy for breast cancer for more than the last thirty years. Moreover, they have been also used for the treatment of ovarian, hormone-refractory prostate, head and neck, and non-small cell lung carcinomas. Even though paclitaxel and docetaxel significantly enhance the overall survival rate of cancer patients, there are some limitations of their use, such as very poor water solubility and the occurrence of severe side effects. However, this is what pushes the research on these microtubule-stabilizing agents further and yields novel taxane derivatives with significantly improved properties. Therefore, this review article brings recent advances reported in taxane research mainly in the last two years. We focused especially on recent methods of taxane isolation, their mechanism of action, development of their novel derivatives, formulations, and improved tumor-targeted drug delivery. Since cancer cell chemoresistance can be an unsurpassable hurdle in taxane administration, a significant part of this review article has been also devoted to combination therapy of taxanes in cancer treatment. Last but not least, we summarize ongoing clinical trials on these compounds and bring a perspective of advancements in this field.

Cardiac Glycosides as Immune System Modulators

“…Currently, they are being clinically tested mostly against cancer, since by triggering the NKA signalosome, CGs can induce apoptosis. However, what makes CGs exceptional among other anticancer drug candidates such as antimitotics [ 82 , 83 ]? In this review article, we showed that the great advantage of CGs in anticancer treatment is the induction of ICD.…”

Vorinostat (SAHA) and Breast Cancer: An Overview

“…The role of taxanes in monochemotherapy or in combination with other active agents has suggested their potential therapeutic impact on the treatment of patients with early BC. Recent studies in the adjuvant setting have shown that taxanes, used individually or in combinations, possess the capability to induce significant improvement in terms of survival of BC patients [ 130 , 131 ].…”

Autophagy Induction by Trichodermic Acid Attenuates Endoplasmic Reticulum Stress-Mediated Apoptosis in Colon Cancer Cells

“…In recent years, natural products have aroused people’s interest in the development of new anticancer therapeutic drugs [ 61 , 62 , 63 ], because most of them show good potential of medicinal significance, which can be used as alternative drugs for the treatment of various diseases (including cancer) with few side effects relatively [ 64 , 65 ]. TDA is a newly discovered octahydronaphthalene derivative, isolated from the secondary metabolites of plant endophytic fungi, and has shown anticancer activity in a variety of cancers [ 12 , 13 ].…”